A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities

Owen, 2013, Targeting HER2+breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles, J Control Release, 172, 395, 10.1016/j.jconrel.2013.07.011

Burstein, 2005, The distinctive nature of HER2-positive breast cancers, N Engl J Med, 353, 1652, 10.1056/NEJMp058197

Ruschoff, 2012, HER2 testing in gastric cancer: a practical approach, Mod Pathol, 25, 637, 10.1038/modpathol.2011.198

Meza-Junco, 2011, Critical appraisal of trastuzumab in treatment of advanced stomach cancer, Cancer Manag Res, 3, 57, 10.2147/CMAR.S12698

Chiosea, 2015, Molecular characterization of apocrine salivary duct carcinoma, Am J Surg Pathol, 39, 744, 10.1097/PAS.0000000000000410

Santin, 2008, Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu, Int J Gynecol Obstet, 102, 128, 10.1016/j.ijgo.2008.04.008

Vasconcellos, 2013, Generation and characterization of new HER2 monoclonal antibodies, Acta Histochem, 115, 240, 10.1016/j.acthis.2012.07.003

Pollock, 2015, HER2 as a therapeutic target in head and neck squamous cell carcinoma, Clin Cancer Res, 21, 526, 10.1158/1078-0432.CCR-14-1432

Doshi, 2014, In vitro nanobody discovery for integral membrane protein targets, Sci Rep, 4, 10.1038/srep06760

Van de, 2011, Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy, ACS Nano, 5, 4319, 10.1021/nn1023363

van der Linden, 1999, Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies, Biochim Biophys Acta, 1431, 37, 10.1016/S0167-4838(99)00030-8

Stewart, 2007, Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naive phage display library: preliminary findings for antivenom development, Toxicon, 49, 699, 10.1016/j.toxicon.2006.11.023

Vaneycken, 2011, Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer, FASEB J, 25, 2433, 10.1096/fj.10-180331

Shahsavarian, 2014, Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries, J Immunol Methods, 407, 26, 10.1016/j.jim.2014.03.015

Arbabi Ghahroudi, 1997, Selection and identification of single domain antibody fragments from camel heavy-chain antibodies, FEBS Lett, 414, 521, 10.1016/S0014-5793(97)01062-4

Vincke, 2012, Generation of single domain antibody fragments derived from camelids and generation of manifold constructs, Methods Mol Biol, 907, 145, 10.1007/978-1-61779-974-7_8

Pavoni, 2014, Optimized selection of anti-tumor recombinant antibodies from phage libraries on intact cells, Mol Immunol, 57, 317, 10.1016/j.molimm.2013.10.009

Yuan, 2015, Development of single chain variable fragment (scFv) antibodies against Xylella fastidiosa subsp. pauca by phage display, J Microbiol Methods, 117, 148, 10.1016/j.mimet.2015.07.020

Aghebati-Maleki, 2016, Phage display as a promising approach for vaccine development, J Biomed Sci, 23, 66, 10.1186/s12929-016-0285-9

Hust, 2002, The production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease, J Virol Methods, 106, 225, 10.1016/S0166-0934(02)00166-0

Sharifzadeh, 2013, Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen, Mol Biotechnol, 54, 590, 10.1007/s12033-012-9601-0

Suo, 2015, y Phage display for identifying peptides that bind the spike protein of transmissible gastroenteritis virus and possess diagnostic potential, Virus Genes, 51, 51, 10.1007/s11262-015-1208-7

Xing, 2017, BiHC, a T-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells, Transl Oncol, 10, 780, 10.1016/j.tranon.2017.07.003

Subedi, 2015, High yield expression of recombinant human proteins with the transient transfection of HEK293 Cells in suspension, J Vis Exp, e53568

Li, 2015, A novel bispecific antibody, S-Fab, induces potent cancer cell killing, J Immunother, 38, 350, 10.1097/CJI.0000000000000099

Dong, 2016, A novel bispecific antibody, BiSS, with potent anti-cancer activities, Cancer Biol Ther, 10.1080/15384047.2016.1139266

Bagheri, 2017, Selection of single chain antibody fragments binding to the extracellular domain of 4-1BB receptor by phage display technology, Tumour Biol, 39, 10.1177/1010428317695924

Li, 2016, A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells, AMB Express, 6, 10.1186/s13568-016-0201-4

Xenaki, 2017, Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors, Front Immunol, 8, 1287, 10.3389/fimmu.2017.01287

Kijanka, 2015, S Oliveira and PM van Bergen En Henegouwen, Nanobody-based cancer therapy of solid tumors, Nanomedicine, 10, 161, 10.2217/nnm.14.178

Cortez-Retamozo, 2004, Efficient cancer therapy with a nanobody-based conjugate, Cancer Res, 64, 2853, 10.1158/0008-5472.CAN-03-3935

Dumoulin, 2002, Single-domain antibody fragments with high conformational stability, Protein Sci, 11, 500, 10.1110/ps.34602

Chen, 2015, A targeted IL-15 fusion protein with potent anti-tumor activity, Cancer Biol Ther, 16, 1415, 10.1080/15384047.2015.1071739

Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155

Mary, 2013, Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain, MAbs, 5, 47, 10.4161/mabs.22697

Smith, 1985, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science, 228, 1315, 10.1126/science.4001944

Swain, 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 372, 724, 10.1056/NEJMoa1413513

Swain, 2013, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 14, 461, 10.1016/S1470-2045(13)70130-X

Rockberg, 2009, Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies, Mol Oncol, 3, 238, 10.1016/j.molonc.2009.01.003